Mechanistic model of hormonal contraception.
Contraceptive drugs intended for family planning are used by the majority of married or in-union women in almost all regions of the world. The two most prevalent types of hormones associated with contraception are synthetic estrogens and progestins. Hormonal based contraceptives contain a dose of a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-06-01
|
| Series: | PLoS Computational Biology |
| Online Access: | https://doi.org/10.1371/journal.pcbi.1007848 |
| _version_ | 1818584869465227264 |
|---|---|
| author | A Armean Wright Ghassan N Fayad James F Selgrade Mette S Olufsen |
| author_facet | A Armean Wright Ghassan N Fayad James F Selgrade Mette S Olufsen |
| author_sort | A Armean Wright |
| collection | DOAJ |
| description | Contraceptive drugs intended for family planning are used by the majority of married or in-union women in almost all regions of the world. The two most prevalent types of hormones associated with contraception are synthetic estrogens and progestins. Hormonal based contraceptives contain a dose of a synthetic progesterone (progestin) or a combination of a progestin and a synthetic estrogen. In this study we use mathematical modeling to understand better how these contraceptive paradigms prevent ovulation, special focus is on understanding how changes in dose impact hormonal cycling. To explain this phenomenon, we added two autocrine mechanisms essential to achieve contraception within our previous menstrual cycle models. This new model predicts mean daily blood concentrations of key hormones during a contraceptive state achieved by administering progestins, synthetic estrogens, or a combined treatment. Model outputs are compared with data from two clinical trials: one for a progestin only treatment and one for a combined hormonal treatment. Results show that contraception can be achieved with synthetic estrogen, with progestin, and by combining the two hormones. An advantage of the combined treatment is that a contraceptive state can be obtained at a lower dose of each hormone. The model studied here is qualitative in nature, but can be coupled with a pharmacokinetic/pharamacodynamic (PKPD) model providing the ability to fit exogenous inputs to specific bioavailability and affinity. A model of this type may allow insight into a specific drug's effects, which has potential to be useful in the pre-clinical trial stage identifying the lowest dose required to achieve contraception. |
| first_indexed | 2024-12-16T08:28:02Z |
| format | Article |
| id | doaj.art-9e2575fea3704aa5a20403f8b94ac14c |
| institution | Directory Open Access Journal |
| issn | 1553-734X 1553-7358 |
| language | English |
| last_indexed | 2024-12-16T08:28:02Z |
| publishDate | 2020-06-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Computational Biology |
| spelling | doaj.art-9e2575fea3704aa5a20403f8b94ac14c2022-12-21T22:37:57ZengPublic Library of Science (PLoS)PLoS Computational Biology1553-734X1553-73582020-06-01166e100784810.1371/journal.pcbi.1007848Mechanistic model of hormonal contraception.A Armean WrightGhassan N FayadJames F SelgradeMette S OlufsenContraceptive drugs intended for family planning are used by the majority of married or in-union women in almost all regions of the world. The two most prevalent types of hormones associated with contraception are synthetic estrogens and progestins. Hormonal based contraceptives contain a dose of a synthetic progesterone (progestin) or a combination of a progestin and a synthetic estrogen. In this study we use mathematical modeling to understand better how these contraceptive paradigms prevent ovulation, special focus is on understanding how changes in dose impact hormonal cycling. To explain this phenomenon, we added two autocrine mechanisms essential to achieve contraception within our previous menstrual cycle models. This new model predicts mean daily blood concentrations of key hormones during a contraceptive state achieved by administering progestins, synthetic estrogens, or a combined treatment. Model outputs are compared with data from two clinical trials: one for a progestin only treatment and one for a combined hormonal treatment. Results show that contraception can be achieved with synthetic estrogen, with progestin, and by combining the two hormones. An advantage of the combined treatment is that a contraceptive state can be obtained at a lower dose of each hormone. The model studied here is qualitative in nature, but can be coupled with a pharmacokinetic/pharamacodynamic (PKPD) model providing the ability to fit exogenous inputs to specific bioavailability and affinity. A model of this type may allow insight into a specific drug's effects, which has potential to be useful in the pre-clinical trial stage identifying the lowest dose required to achieve contraception.https://doi.org/10.1371/journal.pcbi.1007848 |
| spellingShingle | A Armean Wright Ghassan N Fayad James F Selgrade Mette S Olufsen Mechanistic model of hormonal contraception. PLoS Computational Biology |
| title | Mechanistic model of hormonal contraception. |
| title_full | Mechanistic model of hormonal contraception. |
| title_fullStr | Mechanistic model of hormonal contraception. |
| title_full_unstemmed | Mechanistic model of hormonal contraception. |
| title_short | Mechanistic model of hormonal contraception. |
| title_sort | mechanistic model of hormonal contraception |
| url | https://doi.org/10.1371/journal.pcbi.1007848 |
| work_keys_str_mv | AT aarmeanwright mechanisticmodelofhormonalcontraception AT ghassannfayad mechanisticmodelofhormonalcontraception AT jamesfselgrade mechanisticmodelofhormonalcontraception AT mettesolufsen mechanisticmodelofhormonalcontraception |